Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Brad Margus
AddedMar 31, 2024
UpdatedMay 31, 2026
Brad Margus

Brad Margus

Board Member, Cerevance

CrunchbaseLinkedIn

Brad Margus's Career

Cerevance
Cerevance

Cambridge, MA, US

Board Member· Board
Second Genome
Second Genome

South San Francisco, CA, US

Board Member· Board
Perlegen Sciences
Perlegen Sciences

Mountain View, CA, US

Board Member· Board
Neurona Therapeutics
Neurona Therapeutics

South San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Brad Margus's Career

Cerevance
Cerevance
Series B$142.5M622016Cambridge, MA, US
Board Member· Board

Leadership at Cerevance

Mike PooleMike PooleBoard Member
Mark CarltonMark CarltonCo-Founder
Craig ThompsonCraig ThompsonCEO
Matthias KleinzMatthias KleinzBoard Member
David C. LubnerDavid C. LubnerBoard Member

Similar to Cerevance

NeurolinkNeurolinkSan Antonio, TX, USMedical Devicesest. 2008NeurolinkSan Antonio, TX, US · est. 2008

Neurolink Medical, Inc.: Pioneering CNS disorder treatments from San Jose, California.

Seed · $3.9M23
Neuron23Neuron23South San Francisco, CA, USPrecision Medicinesest. 2018Neuron23South San Francisco, CA, US · est. 2018

Neuron23™ Inc.: Developing precision medicines for specific neurological and immunological diseases.

Series C · $213.5M61
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Chase TherapeuticsChase TherapeuticsWashington, D.C., DC, USPharmaceuticalsest. 2017Chase TherapeuticsWashington, D.C., DC, US · est. 2017

Chase Therapeutics: An early-stage pharmaceutical company innovating superior brain disease treatments.

Series B · $25.3M175
Second Genome
Second Genome
Acquired$62.5M02009South San Francisco, CA, US
Board Member· Board

Leadership at Second Genome

Corey GoodmanCorey GoodmanBoard Member
Jill CarrollJill CarrollBoard Member
Jason LettmannJason LettmannBoard Member
Janet WarringtonJanet WarringtonCo-Founder
Todd DeSantisTodd DeSantisCo-Founder
Karim DabbaghKarim DabbaghBoard Member
Perlegen Sciences
Perlegen Sciences
Acquired$154M02000Mountain View, CA, US
Board Member· Board
Neurona Therapeutics
Neurona Therapeutics
Series A$200.3M582008South San Francisco, CA, US
Board Member· Board

Leadership at Neurona Therapeutics

Erica WhittakerErica WhittakerBoard Member
David GoeddelDavid GoeddelBoard Member
Cory R NicholasCory R NicholasFounder

Similar to Neurona Therapeutics

Neurana PharmaceuticalsNeurana PharmaceuticalsSan Diego, CA, USPharmaceuticalsest. 2013Neurana PharmaceuticalsSan Diego, CA, US · est. 2013

Neurana Pharmaceuticals: A US-based specialty pharma company innovating treatments for CNS diseases.

Series A · $60M5
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
NeuronascentNeuronascentClarksville, MD, USTherapeuticsest. 2004NeuronascentClarksville, MD, US · est. 2004

US-based Neuronascent develops pioneering therapeutics for neurodegenerative diseases and depression.

Pre-Seed · $1.3M5
Neuron23Neuron23South San Francisco, CA, USPrecision Medicinesest. 2018Neuron23South San Francisco, CA, US · est. 2018

Neuron23™ Inc.: Developing precision medicines for specific neurological and immunological diseases.

Series C · $213.5M61

Brad Margus's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Brad Margus

Greg CritchfieldGreg CritchfieldBoard Member · Sera PrognosticsSteve WarneckeSteve WarneckeBoard Member · Rockies Venture ClubKevin ConroyKevin ConroyBoard Member · Exact SciencesMike KleinMike KleinCEO · GenomenonDrew SpaventaDrew SpaventaCo-Founder · Axon VenturesKrishna jayaramanKrishna jayaramanBoard Member · Genomics USA